H.B. Fuller Co. Reports Robust Q2 Earnings and Announces £715 Million Acquisition of Advanced Medical Solutions

H.B. Fuller Co. (NYSE: FUL) released its second‑quarter 2026 financial results on June 25, 2026, demonstrating a solid earnings performance that surpassed market expectations. The company’s earnings per share rose to $1.28, a 12 % increase from the prior year’s $1.14, while operating income climbed to $211 million, reflecting efficient cost controls across its global adhesive and specialty chemical businesses.

Earnings Highlights

  • Revenue: $2.02 billion, up 8.5 % YoY, driven primarily by higher sales in the North American and European markets.
  • EBITDA: $245 million, translating to an EBITDA margin of 12.1 %.
  • Adjusted EBITDA Guidance: The management team reiterated an EBITDA range of $650 million–$675 million for FY 2026, underscoring confidence in continued top‑line growth.
  • Free Cash Flow: $98 million, sufficient to fund the planned acquisition and support ongoing dividend and share‑repurchase programs.

Advanced Medical Solutions (AMS) Acquisition

In a strategic move to diversify its portfolio, H.B. Fuller announced a cash‑based offer to acquire Advanced Medical Solutions (AMS) of the United Kingdom for £715 million (approximately $942 million, including debt). The deal, valued at 285 pence per AMS share, positions H.B. Fuller as a significant player in the wound care and tissue‑repair sector—an area that complements its existing adhesive technologies.

The acquisition is expected to deliver:

  • Revenue Synergies: Estimated to contribute $150 million in incremental revenue over the next three years through cross‑selling opportunities and expanded distribution networks.
  • Cost Synergies: Projected savings of $30 million annually from consolidated R&D, procurement, and manufacturing operations.
  • Strategic Fit: AMS’s focus on advanced wound‑healing products aligns with H.B. Fuller’s long‑standing commitment to health‑care and industrial solutions, offering a platform for future innovation.

Market Reaction

Following the earnings announcement, the stock traded down modestly, with a decline of 2.7 % on the day. The dip was attributed to a slightly lower than expected volume outlook, which the company noted could constrain short‑term liquidity. Despite this, the overall sentiment remained positive, as reflected in the company’s robust guidance and the strategic value of the AMS deal.

Investors noted that H.B. Fuller’s share price, which closed at $64.60 on June 23, remains well within its 52‑week range of $48.71–$68.63. The current price‑to‑earnings ratio of 22.01 indicates that the market values the company for its earnings potential and future growth prospects.

Forward‑Looking Statements

During the earnings call, management emphasized that the acquisition of AMS would be completed in Q3 2026, subject to customary regulatory approvals and shareholder consent. H.B. Fuller will continue to focus on organic growth within its core chemical businesses while leveraging AMS’s technology pipeline to accelerate development in the rapidly expanding wound‑care market.

Conclusion

H.B. Fuller’s Q2 earnings beat, coupled with its ambitious £715 million acquisition of Advanced Medical Solutions, signals a decisive shift toward broader health‑care applications. The company’s ability to deliver solid financial results while pursuing strategic diversification positions it favorably for sustained shareholder value creation over the coming years.